Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Inflammation Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1661644

Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis

Provisionally accepted
Ying  JiangYing Jiang1Zhenghui  HuangZhenghui Huang2Ting  ZhouTing Zhou1Mi  WuMi Wu1Juan  ZhaoJuan Zhao1Zheyi  XiongZheyi Xiong1Rui  WangRui Wang1Limin  ChenLimin Chen2Xiufang  WengXiufang Weng1Lan  LinLan Lin2*
  • 1Huazhong University of Science and Technology Tongji Medical College, Wuhan, China
  • 2Fujian Medical University Union Hospital, Fuzhou, China

The final, formatted version of the article will be published soon.

Abstract Background: Pulmonary fibrosis arises from various etiologies, often associated with elevated levels of reactive oxygen species (ROS) stress and activation of pro-fibrotic signaling pathways. The chemotherapeutic drug bleomycin has been shown to exacerbate pulmonary fibrosis during anti-tumor treatment. Further research is needed to combat bleomycin-induced fibrosis. Aim: This investigation aims to identify critical mediators of bleomycin-induced pulmonary fibrosis and evaluate the therapeutic potential of mitochondria-targeted ubiquinone (MitoQ) in attenuating fibrotic pathogenesis. Methods: A bleomycin-induced pulmonary injury mouse model and fibroblast cell culture were established, followed by histopathology evaluation, molecule interaction analysis, cytokine quantification, intervention assay, and flow cytometry. Results: We analyzed RNA-seq data from a bleomycin-induced pulmonary fibrosis mouse model and identified a network of oxidative stress-related fibrosis genes centered on Tgfb1. In fibroblast cell lines, bleomycin exposure elevated mitochondrial and cellular ROS, increased mitochondrial mass and the MDRlow/MTGhigh cell ratio, downregulated genes linked to ROS scavenging and mitochondrial function, and upregulated transcription of pro-fibrotic molecules. MitoQ effectively reduced mitochondrial ROS, alleviated mitochondrial swelling, and restored transcription of genes involved in mitochondrial redox balance and function. Compared to conventional ubiquinone, MitoQ exhibited significantly greater antifibrotic efficacy, effectively attenuating bleomycin- and TGF-β1-induced fibroblast activation in vitro. In bleomycin-treated mice, MitoQ treatment with markedly suppressed pro-fibrotic molecule transcription and inhibited pulmonary fibrosis progression. Conclusions: These findings not only advance our understanding of the interplay between oxidative stress and pro-fibrotic signaling in bleomycin-induced pulmonary fibrosis but also provide experimental data supporting the use of mitochondria-targeted antioxidant in the treatment of this condition.

Keywords: Pulmonary Fibrosis, Bleomycin, Oxidative Stress, pro-fibrotic molecule, mitochondria-targeted ubiquinone (MitoQ)

Received: 08 Jul 2025; Accepted: 27 Aug 2025.

Copyright: © 2025 Jiang, Huang, Zhou, Wu, Zhao, Xiong, Wang, Chen, Weng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lan Lin, Fujian Medical University Union Hospital, Fuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.